MedTrace Logo

Clinical Efficacy and Adverse Reactions of Antipsychotic Treatment

NCT06326840 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-03-22

No results posted yet for this study

Summary

The goal of this clinical trial is to explore the potential of metformin in managing olanzapine-induced metabolic disturbance and hyperprolactinemia in patients with schizophrenia. The main questions it aims to answer are:

1. The effect of metformin on olanzapine-induced metabolic disturbance
2. The effect of metformin on olanzapine-induced hyperprolactinemia

Participants will receive metformin 1500 mg/day for 8 weeks and assessments every 2 weeks.

Conditions

Interventions

DRUG

Metformin

All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.

Sponsors & Collaborators

  • Taipei Medical University

    collaborator OTHER

  • Taipei Medical University Hospital

    lead OTHER

Principal Investigators

  • Mong-Liang Lu, MD · Taipei Meidcal University-Wan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-06-10
Completion
2011-06-10

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326840 on ClinicalTrials.gov